Custom Biomarker Development
We utilize our proprietary single cell CTC platform to develop blood based biomarkers for solid tumor indications with our pharma partners. Measurability is determined by analyzing a patient cohort for:
- CTC prevalence
- CTC phenotypes/genotypes
- Heterogeneity of phenotypes/genotypes
- Associations between specific CTC subtypes and therapeutic responses at decision points and throughout care
The flow diagram (left panel) describes the stepwise biomarker development process and specific tools employed to develop a custom biomarker utilizing Epic Sciences’ proprietary CTC platform. Key questions to be addressed by translational researchers (middle) and the tools used (right) are shown in the figure.
Contact Us to Discuss Custom Biomarker Development
Every time Epic’s AR-V7 test is administered the healthcare system saves about $15,000 per year of life extended. In other words approximately $7,000 to $9,000 per patient tested.
Of the roughly 30 million cells in a typical blood sample, about 5 are cancer cells on their way to form tumors elsewhere in the body. Modern cancer diagnostics technology can't see them.
We spend about $100 billion a year on cancer drugs. But because we’re not matching the right drug to the right patient and their disease in a personalized way, about 3/4ths of that drug spend is wasted.
The Epic approach answers a critical question for a doctor: When is a patient resistant? By answering that question accurately and precisely we increase patient life and save the system money at the same time.
Today, Epic Sciences is embedded in clinical trials with 48 leading producers of oncology drugs and 35 of the top academic cancer hospitals.
It takes only 7 minutes to acquire an entire image of 6 million stained cells on a 1 x 3 slide. Then that image, which is about 20GB of data, gets sent up to the cloud where the algorithms run and find the rare events in about 2 more minutes.